GlassScriptPhysician profile
Douglas C Lanier
NPI 1205825643
$3,056.91
in general payments reported to CMS, 2019-2025
23 companies · $23.46 in 2025
The $23.46 reported for 2025 was less than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $356 · 2020: $163 · 2021: $38.74 · 2022: $680 · 2023: $864 · 2024: $932 · 2025: $23.46.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,798 · Education: $21.35.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,798.05 |
| Education | $21.35 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $505.56 | 2019-2024 | Farxiga, Lokelma |
| Amgen INC. | $374.37 | 2019-2024 | Tavneos |
| Vifor Pharma, INC. | $308.40 | 2019-2024 | Veltassa |
| Fresenius USA Marketing, INC. | $288.53 | 2019-2024 | Velphoro |
| Calliditas Therapeutics US INC. | $220.85 | 2022-2024 | Tarpeyo |
| Otsuka America Pharmaceutical, INC. | $218.43 | 2019-2024 | Jynarque |
| Mallinckrodt Hospital Products INC. | $196.58 | 2020-2024 | Terlivaz, Acthar |
| Nxstage Medical, INC. | $165.92 | 2023 | Nxstage System One |
| Akebia Therapeutics INC | $156.51 | 2019-2024 | Auryxia, Vafseo |
| Cormedix INC. | $105.32 | 2024 | Defencath |
| Opko Pharmaceuticals, LLC | $98.95 | 2020-2024 | Rayaldee |
| Aurinia Pharma U.S., INC. | $97.74 | 2024 | Lupkynis |
| Mallinckrodt Enterprises LLC | $55.97 | 2019 | |
| Horizon Therapeutics Plc | $54.18 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $50.53 | 2023-2024 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $49.55 | 2023 | |
| Janssen Pharmaceuticals, INC | $26.55 | 2019-2020 | |
| Alexion Pharmaceuticals, INC. | $24.22 | 2024 | Ultomiris |
| Pharmacosmos Therapeutics INC. | $22.74 | 2022 | |
| Invivyd INC | $21.80 | 2025 | Pemgarda |
| Renalytix Ai, INC. | $12.55 | 2022 | |
| Travere Therapeutics, INC. | $1.66 | 2025 | Filspari |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Douglas Lanier listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.